Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16905984 | 0.90 | BRD4 (0.54) | ALDH1A1ALOX15ACHEBRD4KMO | |
| SCHEMBL16896900 | 0.84 | BRD4 (0.48) | ALDH1A1ALOX15ACHEBRD4KMO | |
| SCHEMBL20373272 | 0.78 | BRD4 (0.53) | ALDH1A1ALOX15ACHEBRD4KMO | |
| SCHEMBL30665851 | 0.78 | TSHR (0.43) | ALDH1A1BRD4KMOHSD17B10HTR2A | |
| SCHEMBL26654819 | 0.78 | TSHR (0.43) | ALDH1A1BRD4KMOHSD17B10HTR2A | |
| SCHEMBL31457804 | 0.76 | L3MBTL1 (0.40) | ALDH1A1HTR2ADRD2MCHR1TSHR | |
| SCHEMBL26654846 | 0.76 | L3MBTL1 (0.40) | ALDH1A1HTR2ADRD2MCHR1TSHR | |
| SCHEMBL30659620 | 0.76 | NOS3 (0.44) | ALDH1A1KMOHSD17B10HTR2AHTR2C | |
| SCHEMBL26654630 | 0.76 | NOS3 (0.44) | ALDH1A1KMOHSD17B10HTR2AHTR2C | |
| SCHEMBL16905977 | 0.76 | KMO (0.45) | BRD4KMOHSD17B10OPRK1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2020-03-17 | — | — | US | disclosed |
| EP-3092227-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-07-11 | — | — | EP | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| WO-2015104653-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | ALDH1A1 2949/4885ALOX15 2874/4885ACHE 2354/4885 |
| US-10590118-B2 | Bicyclic heterocyclic derivatives as bromodomain inhibitors | BRD1, BRD2, BRD3 | ALDH1A1 2949/4885ALOX15 2874/4885ACHE 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.